/
Pricing Pharmaceuticals: Has Public Policy Delivered? Pricing Pharmaceuticals: Has Public Policy Delivered?

Pricing Pharmaceuticals: Has Public Policy Delivered? - PowerPoint Presentation

pasty-toler
pasty-toler . @pasty-toler
Follow
367 views
Uploaded On 2018-12-04

Pricing Pharmaceuticals: Has Public Policy Delivered? - PPT Presentation

Paul K Gorecki ESRI amp TCD Irish Economic Policy Conference 2014 Economic Policy After the Bailout Institute of Bankers IFC Dublin 31 January 2014 STRUCTURE OF PRESENTATION 2010 What was the problem ID: 734905

amp 2010 pricing pharmaceuticals 2010 amp pharmaceuticals pricing ireland 2013 generic pharmaceutical policy hse expenditure prices high dublin price

Share:

Link:

Embed:

Download Presentation from below link

Download Presentation The PPT/PDF document "Pricing Pharmaceuticals: Has Public Poli..." is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.


Presentation Transcript

Slide1

Pricing Pharmaceuticals: Has Public Policy Delivered?

Paul K Gorecki

ESRI & TCD

Irish Economic Policy Conference 2014: Economic Policy After the Bailout

Institute of Bankers, IFC, Dublin

31 January 2014 Slide2

STRUCTURE OF PRESENTATION

2010: What was the problem?

2013: Towards a successful resolution?

Two Observations on 2010-2013Future Policy: What Remains to be Done?

2Slide3

Ireland High & Rising Pharma

Expenditure:2010

Ireland’s Ranking in

PharmaceuticalExpenditure Per Head Cp

Other OECD Countries:

2000 – 20

th highest of 27 OECD countries 2005 – 9/31 2010 – 3/25

US PharmaceuticalExpenditure Per HeadSet = 100, then Irelandwould be as follows: 2000 – 46 2005 – 58 2010 - 70

3Slide4

High Input & Mediocre Outcome:2010

“In 2010, per capita expenditure spending on

pharmaceuticals in Ireland was the highest in

the EU, 34% above the average, while health

outcomes are not better than the average for

EU countries over a range of high-level

indicators.” European Commission, EconomicAdjustment Programme

for Ireland, Autumn2012.4Slide5

Pharmaceutical Prices: 2010

Generic pharmaceuticals:

Low generic usage cp other MS

High generic prices cp to other MSNew pharmaceuticals:

Consistently high prices cp to other MS

Germany only MS consistently higher prices

Framework for Pricing Decisions:Voluntary DoH/HSE & industry agreementsNo legal basis for generic substitution

5Slide6

Pharmaceutical Pricing: 2013

Framework for Price Setting

Health (Pricing & Supply of Medical Goods) Act 2013

Generic Pharmaceuticals (28% expenditure)

Generic substitution permitted

IMB certified 13 active substances (

statins, ACE inhibitors)

HSE has set reference price for two drugs (atorvastatin, esomeprazole), large decline in priceNew Pharmaceuticals (72% expenditure)Stock -HSE rolling assessment as per the Act (pregabalin)Flow – default status quo or use of Act’s powers?

6Slide7

Two Observations on Pharmaceutical Pricing: 2010-2013

DoH

/HSE strategy since 2009 to reduce pharmaceutical expenditure

through eg reductions in wholesale & pharmacy margins.

2010 – 2013

favourable

conditions for reform of pharmaceutical pricingAgreement on problem/solutionAusterity – greater emphasis on VFMEU-IMF Programme

for Reform for Ireland 7Slide8

Future Policy: What Remains to be Done?

Building on the

Health (Pricing & Supply of Medical Goods) Act 201

What is DoH/HSE policy towards pricing of new drugs?

Release on a monthly basis PCRS data

Quality Adjusted Life Year (QALY)

Is €45,000 threshold the right price?If so, under what conditions, if any, should the threshold be exceeded?

8Slide9

Further reading

P.

Gorecki

, A. Nolan, A. Brick & S Lyons (2012) Delivery of Pharmaceuticals in Ireland. Getting a Bigger Bang for the Buck. RS 24. Dublin: ESRI.A. Brick, P.

Gorecki

& A. Nolan (2013

) Ireland: Pharmaceutical Prices, Prescribing Practices and Usage of Generics in a Comparative Context. RS 32. Dublin: ESRI.

9